|
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
10.1126/scitranslmed.aao3003 2018-04-11 The tumor suppressor p53 is often inactivated via its interaction with endogenous inhibitors mouse double minute 4 homolog (MDM4 or MDMX) or mouse double minute 2 homolog (MDM2), which are frequently overexpressed in patients with acute myeloid leukemia (AML)... |
|
|
T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
10.1126/scitranslmed.aan3311 2018-04-11 Colony-stimulating factor 1 (CSF1) is a key regulator of monocyte/macrophage differentiation that sustains the protumorigenic functions of tumor-associated macrophages (TAMs). We show that CSF1 is expressed in human melanoma, and patients with metastatic mela... |
|
|
Spooked neutrophils unmask sepsis
10.1126/scitranslmed.aat3891 2018-04-11 Microfluidic mazes detect sepsis in patients by monitoring neutrophil motility patterns. |
|
|
Adult neurogenesis in humans: Dogma overturned, again and again?
10.1126/scitranslmed.aat3893 2018-04-11 The controversy continues as to whether new neurons are born in adult human hippocampus. |
|
|
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms
10.1126/scitranslmed.aan8292 2018-04-11 Thrombosis is a major cause of morbidity and mortality in Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), clonal disorders of hematopoiesis characterized by activated Janus kinase (JAK)–signal transducer and activator of transcription (S... |
|
|
Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies
10.1126/scitranslmed.aap9630 2018-04-11 Over the last 60 years, more than a million patients received hematopoietic cell transplantation. Having incorporated multiple changes in clinical practices, it remains a complex procedure facing a dual challenge: cure of the underlying disease and prevention... |
|
|
The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy
10.1126/scitranslmed.aan3464 2018-04-11 Patients undergoing surgical resection of primary breast tumors confront a risk for metastatic recurrence that peaks sharply 12 to 18 months after surgery. The cause of early metastatic relapse in breast cancer has long been debated, with many ascribing these... |
|
|
RNase moonlights as a cancer instigator
10.1126/scitranslmed.aat3892 2018-04-11 RNase 5 is a bona fide EGFR ligand that promotes oncogenic transformation in pancreatic cancer. |
|
|
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
10.1126/scitranslmed.aao5931 2018-04-11 We conducted a pilot clinical trial testing a personalized vaccine generated by autologous dendritic cells (DCs) pulsed with oxidized autologous whole-tumor cell lysate (OCDC), which was injected intranodally in platinum-treated, immunotherapy-naïve, recurren... |
|
|
Fighting leukemia with “duel”-targeted therapy
10.1126/scitranslmed.aat3887 2018-04-04 Combining BCL-2 inhibitor venetoclax with monoclonal CD20 antibody rituximab greatly enhances progression-free survival compared with bendamustine-rituximab in a phase 3 trial of relapsed or refractory chronic lymphocytic leukemia patients. |